Intercept Pharmaceuticals, Inc. Logo
 
Press Releases
Date Title and Summary View
Nov 1, 2017 Worldwide net Ocaliva® (obeticholic acid or OCA) 3Q 2017 sales of $40.9 million (including one-time increase of $4.1M in deferred net revenue)Continuing to advance NASH Phase 3 program: REGENERATE trial in NASH fibrosis on track and NASH cirrhosis trial t...
Oct 25, 2017 NEW YORK, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its third quarter 2017 financial results prior to the...
Oct 23, 2017 OCA met the primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeksResults presented in a late-breaking oral session NEW YORK, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commerciali...
Oct 11, 2017 NEW YORK, Oct. 11, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple obeticholic acid (OCA) abstracts will be presented at The Liver...
Sep 25, 2017 NEW YORK, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today provided comment on the Ocaliva (obeticholic acid or OCA) Dear Healthcare Provider (DH...
Sep 1, 2017 NEW YORK, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:...
Aug 10, 2017 NEW YORK, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:...
Jul 31, 2017 OCA met the primary endpoint of alkaline phosphatase (ALP) reduction at 24 weeksAESOP represents a successful proof of concept for OCA in a second cholestatic liver disease Conference call scheduled for 8:30 a.m. ET today NEW YORK, July 31, 20...
Jul 31, 2017  Low dose atorvastatin rapidly reversed OCA associated LDL changes Conference call scheduled for 8:30 am ET NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on...
Jul 31, 2017 Worldwide net Ocaliva® (obeticholic acid or OCA) 2Q 2017 sales of $30.4 millionAESOP Phase 2 trial in patients with PSC met its primary endpointCONTROL trial met its objective, confirming statin co-administration with OCA red...
Page:
1
... NextLast
= add release to Briefcase